Read by QxMD icon Read


Naoki Aizawa, Daiji Watanabe, Hiroshi Fukuhara, Tetsuya Fujimura, Haruki Kume, Yukio Homma, Yasuhiko Igawa
AIMS: We investigated the effects of silodosin, an α1A-adrenoceptor (AR) antagonist, on bladder function, especially on non-voiding contractions (NVCs), in a male rat model of bladder outlet obstruction (BOO) by evaluating cystometry (CMG) findings and bladder mechanosensitive single-unit afferent activities (SAAs), related with microcontractions, which may be similar with NVCs and to be of myogenic origin, in the rat model. METHODS: BOO was created by partial ligation of the posterior urethra...
March 6, 2018: Neurourology and Urodynamics
Ferdinando Fusco, Massimiliano Creta, Nicola Longo, Francesco Persico, Marco Franco, Vincenzo Mirone
BACKGROUND: To preliminary investigate the effects of silodosin 8 mg once daily on obstruction urodynamic parameters and subjective symptoms in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement. METHODS: We performed a single-center, open-label, single-arm, post-marketing interventional clinical trial. Inclusion criteria were: Caucasian subjects aged ≥50 years waiting to undergo surgery for lower urinary tract symptoms suggestive of benign prostatic enlargement, international prostate symptom total score ≥ 13, international prostate symptom-quality of life score ≥ 3, prostate volume ≥ 30 ml, maximum urine flow rate ≤ 15 mL/s, bladder outlet obstruction index > 40...
March 5, 2018: BMC Urology
Serdar Celik, Firat Akdeniz, Muge Afsar Yildirim, Ozan Bozkurt, Merve Gursoy Bulut, Mehmet Levent Hacihasanoglu, Omer Demir
No abstract text is available yet for this article.
March 2018: Kaohsiung Journal of Medical Sciences
Roderick MacDonald, Michelle Brasure, Philipp Dahm, Carin M Olson, Victoria A Nelson, Howard A Fink, Michael C Risk, Bruce Rwabasonga, Timothy J Wilt
We conducted a systematic review to evaluate the efficacy and adverse effects of newer drugs used to treat lower urinary tract symptoms (LUTS). The drugs were either Food and Drug Administration (FDA) approved for benign prostatic hyperplasia (BPH) or not FDA approved for BPH but have been evaluated for treatment of BPH since 2008. We searched bibliographic databases through September 2017. We included randomized controlled trials (RCTs) lasting one month or longer published in English. Outcomes of interest were LUTS assessed by validated measures...
February 2, 2018: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
Jing Li, Yanxin Tian, Shimeng Guo, Haifeng Gu, Qianting Yuan, Xin Xie
Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms in voiding. In drug development, old male dogs with spontaneous BPH are considered the golden standard of the animal models. However, old dogs (>6 years) are expensive and not all old dogs develop BPH...
2018: PloS One
Ersan Arda, Basri Cakiroglu, Ilkan Yuksel, Esra Akdeniz, Gizem Cetin
Introduction Our aim was to contribute a study that includes a higher patient population to the limited number of studies comparing tamsulosin and silodosin in the treatment of distal ureteral stones. Material and methods Patients who presented with renal colic to the urology emergency clinic and were diagnosed with ureteral stones and followed-up with conservative treatment between January 2010 and January 2016 were retrospectively screened. According to the inclusion-exclusion criteria, the patients were divided into three groups...
November 15, 2017: Curēus
Priyanka A Shah, Pranav S Shrivastav
No abstract text is available yet for this article.
December 13, 2017: Bioanalysis
Rohit Bhattar, Vipin Jain, Vinay Tomar, Sher Singh Yadav
Objective: To evaluate the safety and efficacy of silodosin and tadalafil in ease of negotiation of large size ureteroscope (8/9.8 Fr) in the management of ureteral stone. Material and methods: Between June 2015 and May 2016, 86 patients presented with ureteral stone of size 6-15 mm were on consent randomly assigned to 1 of 3 outpatient treatment arms: silodosin (Group A), tadalafil (Group B), and placebo (Group C). After two weeks of therapy 67 patients underwent ureteroscopy, and ureteral orifice configuration, ureteroscopic negotiation, ureteral dilatation, operating time, procedural complication and drug related side effects were noted in each group...
December 2017: Turkish Journal of Urology
S Masciovecchio, A B Di Pasquale, G Ranieri, G Romano, L Di Clemente
OBJECTIVE: Lower urinary tract symptoms (LUTS) are frequently experienced in association with benign prostatic enlargement (BPE). Current guidelines state that alpha-blockers should be considered the first-line therapy of LUTS associated with BPE in most patients. However, in clinical practice treatment efficacy differs among individuals and, therefore, intra-class switch from one alpha-blocker to another, is frequently applied. In particular, switching to silodosin in clinical practice appears an intriguing therapeutic strategy due to the peculiar pharmacological properties of this molecule...
November 2017: European Review for Medical and Pharmacological Sciences
Jae Hung Jung, Jiye Kim, Roderick MacDonald, Balaji Reddy, Myung Ha Kim, Philipp Dahm
BACKGROUND: A variety of alpha-blockers are used for treating lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Silodosin is a novel, more selective alpha-blocker, which is specific to the lower urinary tract and may have fewer side effects than other alpha-blockers. OBJECTIVES: To assess the effects of silodosin for the treatment of LUTS in men with BPH. SEARCH METHODS: We performed a comprehensive search using multiple databases (Cochrane Library, MEDLINE, EMBASE, Scopus, Google Scholar, and Web of Science), trials registries, other sources of grey literature, and conference proceedings with no restrictions on the language of publication or publication status up until 13 June 2017...
November 22, 2017: Cochrane Database of Systematic Reviews
Mustafa Aydın, Muhammet Fatih Kılınç, Abdulmecit Yavuz, Göksel Bayar
The objective of this study is to assess the efficacy of adjunctive silodosin therapy in improving the success rate of semi-rigid ureteroscopy for removing ureteral stones. Prospective randomised controlled clinical trial performed between July 2016 and September 2016. All the patients underwent ureteroscopic holmium lithotripsy with a YAG laser. The patients were randomised into one of three groups: those who did not use an alpha-1 blocker (AB) (Group 1, n = 50), those who used an AB for one day (Group 2, n = 50), and those who used an AB for three days (Group 3, n = 47)...
November 18, 2017: Urolithiasis
Allen D Seftel
No abstract text is available yet for this article.
December 2017: Journal of Urology
M I Kogan, I I Belousov, A M Yassine
Extracorporeal shock wave lithotripsy (ESWL) has proven efficacy in the treatment of proximal ureteral stones. The research to date has not been able to establish real time to spontaneous stone clearance after ESWL and the appropriateness and effectiveness of -blockers in stimulating residual stone clearance after ESWL. AIM: To conduct a comprehensive assessment of the effectiveness of ESWL in treating proximal ureteral stones and determine the appropriateness of using -blockers to stimulate residual stone clearance...
October 2017: Urologii︠a︡
Luca Boeri, Paolo Capogrosso, Eugenio Ventimiglia, Walter Cazzaniga, Filippo Pederzoli, Donatella Moretti, Federico Dehò, Emanuele Montanari, Francesco Montorsi, Andrea Salonia
To assess the rate and predictors of clinically meaningful improvements (CMI) in patients with lower urinary tract symptoms (LUTS) treated with either silodosin (SIL) alone or with a combination of SIL+ serenoa repens (Ser) hexanic lipidosterolic extract for ≥12 months. Data from 186 patients were collected. Patients completed the International Prostatic Symptoms Score (IPSS) at baseline and at follow-up assessment. Descriptive statistics and logistic regression models tested rates and predictors of CMI. Two CMI were assessed: 1) >3 points improvement in total IPSS from baseline to end (CMI#1); 2) >25% IPSS improvement from baseline to end (CMI#2)...
November 9, 2017: Scientific Reports
Siddangouda B Patil, Kshitiz Ranka, Vinay S Kundargi, Nilesh Guru
Introduction: We present a prospective randomized study to compare the efficacy of tamsulosin and silodosin in patients suffering from acute urinary retention caused by benign prostatic hyperplasia, planned for trial without catheter. Material and methods: Patients with acute urinary retention secondary to benign prostatic hyperplasia (total 160) were catheterized and randomized into two groups: Group A: tamsulosin 0.4 mg (80 patients) and Group B: silodosin 8 mg (80 patients)...
2017: Central European Journal of Urology
Hazem Elgalaly, Ahmed Eliwa, Mohamed Seleem, Emad Salem, Mohammed Omran, Haitham Shello, Khalid Abdelwahab, Salem Khalil, Mostafa Kamel
OBJECTIVES: To evaluate the possible role of silodosin (a highly selective α1A-adrenoceptor antagonist) in facilitating the passage of distal ureteric stones (DUS) in children, as the role of α-blockers as medical expulsive therapy is well known in adults. PATIENTS AND METHODS: In all, 40 paediatric patients (27 boys and 13 girls) diagnosed with unilateral, single, radiopaque DUS of <10 mm were included in the study. Their mean (SD, range) age was 8.1 (2.7, 5-17) years...
September 2017: Arab Journal of Urology
Ashok Kumar Sokhal, Satyanarayan Sankhwar, Apul Goel, Kawaljit Singh, Manoj Kumar, Bimalesh Purkait, Durgesh Kumar Saini
OBJECTIVE-: To evaluate sexual dysfunction and enlargement of seminal vesicles in sexually active male who were treated by α1-blockers for benign prostatic hyperplasia and its possible clinical application. METHODS-: A prospective cohort study from January 2015 to December 2016. We enrolled sexually active men above the age of 40 years having moderate to severe lower urinary tract symptoms. We excluded patients with a history of prostate surgery, suspicious DRE findings, serum PSA >4 ng/dl, history of medication with anticholinergic/cholinergic /diuretic agents...
August 28, 2017: Urology
Saori Yonekubo, Satoshi Tatemichi, Kazuyasu Maruyama, Mamoru Kobayashi
BACKGROUND: Patients with diabetes experience lower urinary tract symptoms. Cystopathy may evolve into underactive bladder (UAB), depending on the degree and duration of the symptoms. In the present study, we aimed to investigate the effects of silodosin, an alpha1A-adrenoceptor (AR) antagonist, on UAB in a rat model of diabetes mellitus (DM). METHODS: Female Sprague-Dawley rats (6 weeks old) were administered streptozotocin (STZ) (50 mg/kg, i.v.) to establish a DM model...
August 23, 2017: BMC Urology
Woo Suk Choi, Min Chul Cho, Jeong Woo Lee, Sang Hoon Song, Jin Kyu Oh, Sang Wook Lee, Sung Yong Cho, Jae Young Park
BACKGROUND: Both hypertension and lower urinary tract symptoms (LUTS) are common conditions in the elderly population. This study investigated the efficacy and safety of silodosin in the treatment of LUTS in elderly men who were taking antihypertensive medications. METHODS: This is an observational study which collected the medical records of patients who started silodosin medication for their LUTS between April 2015 and December 2015. Inclusion criteria were age ≥ 65 years, currently taking antihypertensive medication, and International Prostate Symptom Score (IPSS) ≥ 8...
September 2017: Prostate International
Shinichiro Fukuhara
No abstract text is available yet for this article.
August 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"